Cargando…

Nutritional Strategies to Prevent Muscle Loss and Sarcopenia in Chronic Kidney Disease: What Do We Currently Know?

Loss of muscle mass is an extremely frequent complication in patients with chronic kidney disease (CKD). The etiology of muscle loss in CKD is multifactorial and may depend on kidney disease itself, dialysis, the typical chronic low-grade inflammation present in patients with chronic kidney disease,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massini, Giulia, Caldiroli, Lara, Molinari, Paolo, Carminati, Francesca Maria Ida, Castellano, Giuseppe, Vettoretti, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384728/ https://www.ncbi.nlm.nih.gov/pubmed/37513525 http://dx.doi.org/10.3390/nu15143107

Ejemplares similares

Nutrition and Sarcopenia—What Do We Know?
por: Ganapathy, Aravinda, et al.
Publicado: (2020)

Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease
por: Molinari, Paolo, et al.
Publicado: (2022)

Can Mediterranean Diet Have a Positive Impact on Kidney Health? A Pending Answer to a Long-Time Question
por: Caldiroli, Lara, et al.
Publicado: (2022)

Association of Autofluorescent Advanced Glycation End Products (AGEs) with Frailty Components in Chronic Kidney Disease (CKD): Data from a Single-Center Cohort Study
por: Molinari, Paolo, et al.
Publicado: (2023)

Sarcopenia is Associated with Malnutrition but Not with Systemic Inflammation in Older Persons with Advanced CKD
por: Vettoretti, Simone, et al.
Publicado: (2019)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease
por: Dozio, Elena, et al.
Publicado: (2023)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

Possible Benefits of a Low Protein Diet in Older Patients With CKD at Risk of Malnutrition: A Pilot Randomized Controlled Trial
por: Caldiroli, Lara, et al.
Publicado: (2022)

In Patients with Chronic Kidney Disease Advanced Glycation End-Products Receptors Isoforms (sRAGE and esRAGE) Are Associated with Malnutrition
por: Caldiroli, Lara, et al.
Publicado: (2022)

Anxiety and Depression: What Do We Know of Neuropeptides?
por: Kupcova, Ida, et al.
Publicado: (2022)

Transmission of Ebola Viruses: What We Know and What We Do Not Know
por: Osterholm, Michael T., et al.
Publicado: (2015)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Cerebrospinal fluid circulation: What do we know and how do we know it?
por: Khasawneh, Ahmad H, et al.
Publicado: (2018)

Metal wear particles: What we know, what we do not know, and why
por: Billi, Fabrizio, et al.
Publicado: (2009)

Mechanisms of atrial fibrillation in athletes: what we know and what we do not know
por: Guasch, E., et al.
Publicado: (2018)

Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)

Ticks and Tularemia: Do We Know What We Don't Know?
por: Zellner, Briana, et al.
Publicado: (2019)

Diet, nutrition, and cancer risk: what do we know and what is the way forward?
por: Key, Timothy J, et al.
Publicado: (2020)

What Do We Know about Suicide Bereavement, and What We Can Do to Help Suicide-Loss Survivors?
por: Levi-Belz, Yossi, et al.
Publicado: (2023)

Cardiac surgery and the coronavirus disease 2019 pandemic: What we know, what we do not know, and what we need to do
por: Bakaeen, Faisal G., et al.
Publicado: (2020)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

The Role of Testosterone in the Elderly: What Do We Know?
por: Barone, Biagio, et al.
Publicado: (2022)

Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know
por: Sun, Chuan-bin, et al.
Publicado: (2020)

The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know
por: Goldstein, David S.
Publicado: (2021)

Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
por: Boziki, Marina Kleopatra, et al.
Publicado: (2020)

The risk of viral transmission in feed: What do we know, what do we do?
por: Dee, Scott A., et al.
Publicado: (2020)

Experimental subjects do not know what we think they know
por: Field, Jared M., et al.
Publicado: (2020)

Health Statistics in Australia: What We Know and Do Not Know
por: Madden, Richard, et al.
Publicado: (2022)

Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?
por: Shapter, Frances Marie, et al.
Publicado: (2023)

Kiwifruit’s Allergy in Children: What Do We Know?
por: Bringheli, Ivana, et al.
Publicado: (2023)

Hearing Loss in SARS-CoV-2: What Do We Know?
por: Saniasiaya, Jeyasakthy
Publicado: (2021)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Multinational monkeypox outbreak: what do we know and what should we do?
por: Memariani, Mojtaba, et al.
Publicado: (2022)

Sodium and brain injury: do we know what we are doing?
por: Zygun, David A
Publicado: (2009)

COVID-19 and cancer: do we really know what we think we know?
por: Robinson, Andrew G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_319eqg1qcekjkspaispj7oamoq